Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as lenalidomide use different ways to stimulate the
immune system and stop cancer cells from growing. Monoclonal antibodies such as rituximab can
locate cancer cells and either kill them or deliver cancer-killing substances to them without
harming normal cells. Combining lenalidomide with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying the how well giving lenalidomide with or without
rituximab works in treating patients with relapsed or refractory chronic lymphocytic
leukemia.